The Danish pharmaceutical company Novo Nordisk have won European approval for their diabetes drug Victoza. The European Commission approved the drug for marketing across the European Union. The European Medicines Agency had already offered a positive opinion.
Novo Nordisk praised the decision as a milestone, reportedly commented: “The European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.”
The company will launch the drug throughout Britai, Denmark and Germany this summer. Victoza has previously been the subject of concerns over safety profile, with the Food and Drug Administration returning a split vote for approval in the US market.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…